Literature DB >> 25600808

Dissociation of glucocerebrosidase dimer in solution by its co-factor, saposin C.

James M Gruschus1, Zhiping Jiang2, Thai Leong Yap2, Stephanie A Hill2, Alexander Grishaev3, Grzegorz Piszczek4, Ellen Sidransky5, Jennifer C Lee6.   

Abstract

Mutations in the gene for the lysosomal enzyme glucocerebrosidase (GCase) cause Gaucher disease and are the most common risk factor for Parkinson disease (PD). Analytical ultracentrifugation of 8 μM GCase shows equilibrium between monomer and dimer forms. However, in the presence of its co-factor saposin C (Sap C), only monomer GCase is seen. Isothermal calorimetry confirms that Sap C associates with GCase in solution in a 1:1 complex (Kd = 2.1 ± 1.1 μM). Saturation cross-transfer NMR determined that the region of Sap C contacting GCase includes residues 63-66 and 74-76, which is distinct from the region known to enhance GCase activity. Because α-synuclein (α-syn), a protein closely associated with PD etiology, competes with Sap C for GCase binding, its interaction with GCase was also measured by ultracentrifugation and saturation cross-transfer. Unlike Sap C, binding of α-syn to GCase does not affect multimerization. However, adding α-syn reduces saturation cross-transfer from Sap C to GCase, confirming displacement. To explore where Sap C might disrupt multimeric GCase, GCase x-ray structures were analyzed using the program PISA, which predicted stable dimer and tetramer forms. For the most frequently predicted multimer interface, the GCase active sites are partially buried, suggesting that Sap C might disrupt the multimer by binding near the active site. Published by Elsevier Inc.

Entities:  

Keywords:  AUC; Gaucher disease; NMR; Parkinson disease; α-synuclein

Mesh:

Substances:

Year:  2015        PMID: 25600808      PMCID: PMC4361889          DOI: 10.1016/j.bbrc.2015.01.024

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  30 in total

1.  Penetrance of PD in Glucocerebrosidase Gene Mutation Carriers.

Authors:  Ellen Sidransky; P Suzanne Hart
Journal:  Neurology       Date:  2012-07-03       Impact factor: 9.910

2.  High-precision isothermal titration calorimetry with automated peak-shape analysis.

Authors:  Sandro Keller; Carolyn Vargas; Huaying Zhao; Grzegorz Piszczek; Chad A Brautigam; Peter Schuck
Journal:  Anal Chem       Date:  2012-05-14       Impact factor: 6.986

3.  Functional organization of saposin C. Definition of the neurotrophic and acid beta-glucosidase activation regions.

Authors:  X Qi; W Qin; Y Sun; K Kondoh; G A Grabowski
Journal:  J Biol Chem       Date:  1996-03-22       Impact factor: 5.157

Review 4.  Exploring the link between glucocerebrosidase mutations and parkinsonism.

Authors:  Wendy Westbroek; Ann Marie Gustafson; Ellen Sidransky
Journal:  Trends Mol Med       Date:  2011-07-01       Impact factor: 11.951

5.  CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy.

Authors:  S Pablo Sardi; Jennifer Clarke; Cathrine Kinnecom; Thomas J Tamsett; Lingyun Li; Lisa M Stanek; Marco A Passini; Gregory A Grabowski; Michael G Schlossmacher; Richard L Sidman; Seng H Cheng; Lamya S Shihabuddin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-05       Impact factor: 11.205

6.  Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.

Authors:  Joseph R Mazzulli; You-Hai Xu; Ying Sun; Adam L Knight; Pamela J McLean; Guy A Caldwell; Ellen Sidransky; Gregory A Grabowski; Dimitri Krainc
Journal:  Cell       Date:  2011-06-23       Impact factor: 41.582

7.  Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.

Authors:  Thai Leong Yap; James M Gruschus; Arash Velayati; Wendy Westbroek; Ehud Goldin; Nima Moaven; Ellen Sidransky; Jennifer C Lee
Journal:  J Biol Chem       Date:  2011-06-08       Impact factor: 5.157

Review 8.  The role of saposin C in Gaucher disease.

Authors:  Rafael J Tamargo; Arash Velayati; Ehud Goldin; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2012-05-05       Impact factor: 4.797

9.  Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing.

Authors:  Valerie Cullen; S Pablo Sardi; Juliana Ng; You-Hai Xu; Ying Sun; Julianna J Tomlinson; Piotr Kolodziej; Ilana Kahn; Paul Saftig; John Woulfe; Jean-Christophe Rochet; Marcie A Glicksman; Seng H Cheng; Gregory A Grabowski; Lamya S Shihabuddin; Michael G Schlossmacher
Journal:  Ann Neurol       Date:  2011-04-06       Impact factor: 10.422

10.  Disease-causing mutations within the lysosomal integral membrane protein type 2 (LIMP-2) reveal the nature of binding to its ligand beta-glucocerebrosidase.

Authors:  Judith Blanz; Johann Groth; Christina Zachos; Christina Wehling; Paul Saftig; Michael Schwake
Journal:  Hum Mol Genet       Date:  2009-11-20       Impact factor: 6.150

View more
  10 in total

1.  β-Glucocerebrosidase Modulators Promote Dimerization of β-Glucocerebrosidase and Reveal an Allosteric Binding Site.

Authors:  Jianbin Zheng; Long Chen; Owen S Skinner; Daniel Ysselstein; Jonathan Remis; Peter Lansbury; Renato Skerlj; Michael Mrosek; Ursula Heunisch; Stephan Krapp; Joel Charrow; Michael Schwake; Neil L Kelleher; Richard B Silverman; Dimitri Krainc
Journal:  J Am Chem Soc       Date:  2018-04-30       Impact factor: 15.419

Review 2.  The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease.

Authors:  Elma Aflaki; Wendy Westbroek; Ellen Sidransky
Journal:  Neuron       Date:  2017-02-22       Impact factor: 17.173

3.  Prosaposin Reduces α-Synuclein in Cells and Saposin C Dislodges it from Glucosylceramide-enriched Lipid Membranes.

Authors:  Rika Kojima; Mark Zurbruegg; Tianyi Li; Wojciech Paslawski; Xiaoqun Zhang; Per Svenningsson
Journal:  J Mol Neurosci       Date:  2022-09-24       Impact factor: 2.866

4.  Distinguishing the differences in β-glycosylceramidase folds, dynamics, and actions informs therapeutic uses.

Authors:  Fredj Ben Bdira; Marta Artola; Herman S Overkleeft; Marcellus Ubbink; Johannes M F G Aerts
Journal:  J Lipid Res       Date:  2018-10-02       Impact factor: 5.922

5.  Genetic Analysis of Prosaposin, the Lysosomal Storage Disorder Gene in Parkinson's Disease.

Authors:  Yong-Ping Chen; Xiao-Jing Gu; Ru-Wei Ou; Ling-Yu Zhang; Yan-Bing Hou; Kun-Cheng Liu; Bei Cao; Qian-Qian Wei; Wei Song; Bi Zhao; Ying Wu; Jing-Qiu Cheng; Hui-Fang Shang
Journal:  Mol Neurobiol       Date:  2020-11-20       Impact factor: 5.590

Review 6.  A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.

Authors:  Jérôme Stirnemann; Nadia Belmatoug; Fabrice Camou; Christine Serratrice; Roseline Froissart; Catherine Caillaud; Thierry Levade; Leonardo Astudillo; Jacques Serratrice; Anaïs Brassier; Christian Rose; Thierry Billette de Villemeur; Marc G Berger
Journal:  Int J Mol Sci       Date:  2017-02-17       Impact factor: 5.923

Review 7.  Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.

Authors:  Tapan Behl; Gagandeep Kaur; Ovidiu Fratila; Camelia Buhas; Claudia Teodora Judea-Pusta; Nicoleta Negrut; Cristiana Bustea; Simona Bungau
Journal:  Transl Neurodegener       Date:  2021-01-15       Impact factor: 8.014

Review 8.  GCase Enhancers: A Potential Therapeutic Option for Gaucher Disease and Other Neurological Disorders.

Authors:  Macarena Martínez-Bailén; Francesca Clemente; Camilla Matassini; Francesca Cardona
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-02

9.  Did α-Synuclein and Glucocerebrosidase Coevolve? Implications for Parkinson's Disease.

Authors:  James M Gruschus
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

10.  3,4,5-Trihydroxypiperidine Based Multivalent Glucocerebrosidase (GCase) Enhancers.

Authors:  Costanza Vanni; Francesca Clemente; Paolo Paoli; Amelia Morrone; Camilla Matassini; Andrea Goti; Francesca Cardona
Journal:  Chembiochem       Date:  2022-04-07       Impact factor: 3.461

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.